Gordon Cook

Summary

Affiliation: St James's University Hospital
Country: UK

Publications

  1. doi request reprint Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation
    Gordon Cook
    St James s Institute of Oncology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom
    Biol Blood Marrow Transplant 16:1419-27. 2010
  2. doi request reprint In pursuit of the allo-immune response in multiple myeloma: where do we go from here?
    G Cook
    BMTU, St James s Institute of Oncology, Leeds Teaching Hospitals Trust, Leeds, UK
    Bone Marrow Transplant 43:91-9. 2009
  3. doi request reprint The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis
    G Cook
    Department of Haematology, St James s Institute of Oncology, Leeds Teaching Hospitals Trust, Leeds, UK
    Bone Marrow Transplant 46:1210-8. 2011
  4. doi request reprint Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry
    Gordon Cook
    St James s Institute of Oncology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom
    Biol Blood Marrow Transplant 17:1638-45. 2011
  5. ncbi request reprint A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma
    G Cook
    Leeds Teaching Hospitals Trust, Leeds, UK
    Br J Haematol 126:792-8. 2004
  6. doi request reprint Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study
    Andy C Rawstron
    St James s University Hospital, Leeds, United Kingdom
    J Clin Oncol 31:2540-7. 2013
  7. pmc Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission
    Bella Patel
    Department of Haematology, Royal Free and University College London Medical School, and BSBMT Data Registry, Guy s Hospital, London, UK
    Haematologica 94:1399-406. 2009
  8. ncbi request reprint The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy
    Gordon Cook
    St James Hospital, Leeds, and Royal Liverpool University Hospital, United Kingdom
    Biol Blood Marrow Transplant 12:293-300. 2006
  9. pmc Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
    Andy C Rawstron
    St James s University Hospital, Leeds, United Kingdom
    Blood 125:1932-5. 2015
  10. doi request reprint Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009
    John A Snowden
    Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust and Department of Oncology, University of Sheffield, Sheffield, UK
    Br J Haematol 157:742-6. 2012

Collaborators

Detail Information

Publications31

  1. doi request reprint Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation
    Gordon Cook
    St James s Institute of Oncology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom
    Biol Blood Marrow Transplant 16:1419-27. 2010
    ..For patients relapsing post-AlloSCT, the disease is salvageable with DLI. The timing of RIC-AlloSCT should be explored in prospective studies to establish the optimal role in the management of this aggressive lymphoma...
  2. doi request reprint In pursuit of the allo-immune response in multiple myeloma: where do we go from here?
    G Cook
    BMTU, St James s Institute of Oncology, Leeds Teaching Hospitals Trust, Leeds, UK
    Bone Marrow Transplant 43:91-9. 2009
    ....
  3. doi request reprint The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis
    G Cook
    Department of Haematology, St James s Institute of Oncology, Leeds Teaching Hospitals Trust, Leeds, UK
    Bone Marrow Transplant 46:1210-8. 2011
    ..The similarity in OS between the years may reflect the introduction of novel agents in salvage therapy. The reduced PFS in 2005 is as yet not fully explained, but may represent recent disease response criterion standardization...
  4. doi request reprint Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry
    Gordon Cook
    St James s Institute of Oncology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom
    Biol Blood Marrow Transplant 17:1638-45. 2011
    ..Second ASCT in relapsed MM is associated with superior OS and PFS compared with CCT, offering a potential consolidative option for selected patients...
  5. ncbi request reprint A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma
    G Cook
    Leeds Teaching Hospitals Trust, Leeds, UK
    Br J Haematol 126:792-8. 2004
    ..This study demonstrated that Z-Dex might be a suitable oral alternative to VAD for treating newly diagnosed MM patients, although definitive evidence for equivalence is not provided...
  6. doi request reprint Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study
    Andy C Rawstron
    St James s University Hospital, Leeds, United Kingdom
    J Clin Oncol 31:2540-7. 2013
    ..To investigate the prognostic value of minimal residual disease (MRD) assessment in patients with multiple myeloma treated in the MRC (Medical Research Council) Myeloma IX trial...
  7. pmc Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission
    Bella Patel
    Department of Haematology, Royal Free and University College London Medical School, and BSBMT Data Registry, Guy s Hospital, London, UK
    Haematologica 94:1399-406. 2009
    ..Although T-cell depletion abrogates graft-versus-host disease, the impact on disease-free survival in acute lymphoblastic leukemia is not known...
  8. ncbi request reprint The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy
    Gordon Cook
    St James Hospital, Leeds, and Royal Liverpool University Hospital, United Kingdom
    Biol Blood Marrow Transplant 12:293-300. 2006
    ..Further studies are needed to determine the optimal conditioning regimens and GVHD prophylaxis...
  9. pmc Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
    Andy C Rawstron
    St James s University Hospital, Leeds, United Kingdom
    Blood 125:1932-5. 2015
    ..01% MRD). MRD level as a continuous variable determined by flow cytometry independently predicts both PFS and OS, with approximately 1 year median OS benefit per log depletion. The trial was registered at www.isrctn.com as #68454111. ..
  10. doi request reprint Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009
    John A Snowden
    Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust and Department of Oncology, University of Sheffield, Sheffield, UK
    Br J Haematol 157:742-6. 2012
    ..Treatment of poor-risk but reversible SADs with adequate fitness for HSCT in accordance with current guidelines is warranted...
  11. doi request reprint Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma
    Christopher Parrish
    St James s Institute of Oncology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom
    Biol Blood Marrow Transplant 21:1330-4. 2015
    ..Comprehensive multivariate analysis identified no disparate subgroups, meaning ASCT is a reasonable strategy for all fit primary refractory patients. ..
  12. doi request reprint Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease
    Bronwen E Shaw
    Anthony Nolan Trust, London Royal Marsden Hospital, London Imperial College, London, UK
    Br J Haematol 153:244-52. 2011
    ....
  13. doi request reprint Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked
    Marie von Lilienfeld-Toal
    Transplant Immunology Group, Level 3, St James s Institute of Oncology, Bexley Wing, St James s University Hospital, Leeds, LS9 7TF, UK
    Cancer Immunol Immunother 59:829-39. 2010
    ..We analysed the expression of the activating receptor NKG2D on NK cells and T cells of MM patients and investigated the impact of soluble versus membrane-bound NKG2D ligands on the expression of NKG2D...
  14. doi request reprint Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial
    Christopher Parrish
    Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom
    Biol Blood Marrow Transplant 22:1009-16. 2016
    ..The study is registered with ClinicalTrials.gov (NCT00747877) and EudraCT (2006-005890-24). ..
  15. doi request reprint CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden
    Sylvia Feyler
    Transplant Immunology Group, Academic Department of Oncology and Haematology, University of Leeds, Leeds, UK
    Br J Haematol 144:686-95. 2009
    ..This data adds further evidence to the understanding of the role of T(Reg) cell subsets in tumour immunology and the fundamentals of the host/tumour immune conflict...
  16. ncbi request reprint Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma
    Emma Morris
    Department of Haematology, Royal Free and University College Hospitals Medical School, 98 Chenies Mews, London WC1E 6HX, United Kingdom
    Blood 104:3865-71. 2004
    ..Patients who experienced relapses of LG-NHL and chronic lymphocytic leukemia (CLL) achieved excellent PFS with extremely low TRM and GVHD, even when matched related donors were unavailable...
  17. doi request reprint T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma
    Kirsty J Thomson
    Department of Haematology, University College Hospital, London, UK
    J Clin Oncol 28:3695-700. 2010
    ..Thus, reduced-intensity conditioning regimens are being explored...
  18. doi request reprint Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial
    Steve Schey
    Department of Haematology, King s College Hospital, London, UK
    Br J Haematol 170:336-48. 2015
    ..This study demonstrates bendamustine at 60 mg/m2 twice per month with thalidomide and dexamethasone is deliverable for repeated cycles in heavily pre-treated myeloma patients and has substantial clinical activity...
  19. pmc Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent
    Sylvia Feyler
    Transplant Immunology Group, Academic Department of Haematology and Oncology, University of Leeds, Leeds, United Kingdom
    PLoS ONE 7:e35981. 2012
    ..These features suggest that tumour generation of T(Reg) cells may contribute to evasion of immune surveillance by the host...
  20. doi request reprint Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM)
    Sylvia Feyler
    Transplant Immunology Group, Academic Department of Haematology and Oncology, University of Leeds, UK
    Blood Rev 27:155-64. 2013
    ..This review sets out the basic understanding of the human immune response, its dysregulation in cancer and proposes how this knowledge may influence future treatment strategies to maximise the anti-tumour immune response...
  21. ncbi request reprint Observation-based early warning scores to detect impending critical illness predict in-hospital and overall survival in patients undergoing allogeneic stem cell transplantation
    Marie von Lilienfeld-Toal
    BMTU, St James s University Hospital, Leeds, United Kingdom
    Biol Blood Marrow Transplant 13:568-76. 2007
    ..018. This is the first study to validate EWSS in Allo-SCT and demonstrate that these systems are highly predictive of in-hospital and overall survival...
  22. ncbi request reprint The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells
    Yasser M El-Sherbiny
    Leeds Institute of Molecular Medicine, University of Leeds, Wellcome Trust Brenner Building, St James s University Hospital, Leeds, UK
    Cancer Res 67:8444-9. 2007
    ..The importance of NKp46, NKG2D, and DNAM-1 in myeloma killing mirrors the differential expression of NK cell ligands by myeloma cells, reflecting immune selection during myeloma disease progression...
  23. doi request reprint IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14)
    Sylvia Feyler
    Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
    Br J Haematol 140:547-51. 2008
    ..Despite the high incidence of the t(11;14), CD20 was only expressed in one of nine cases. We conclude that IgM myeloma is a distinctive subset characterized by a CD20-CD56-CD117- phenotype and the t(11;14)...
  24. doi request reprint High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label,
    Gordon Cook
    St James s Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, UK Electronic address
    Lancet Oncol 15:874-85. 2014
    ..We aimed to compare high-dose melphalan plus salvage ASCT with cyclophosphamide in patients with relapsed multiple myeloma who had previously undergone ASCT...
  25. ncbi request reprint The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study
    S Feyler
    BMTU, St James s University Hospital, Leeds, UK
    Bone Marrow Transplant 40:443-50. 2007
    ..The use of full-intensity allogeneic transplantation is limited by high transplant-related mortality, and exploration of reduced intensity regimens is warranted...
  26. ncbi request reprint Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes
    R L Jones
    Gastrointestinal Department, Royal Marsden Hospital, Down s Road, Sutton, Surrey SM2 5PT, UK
    Br J Radiol 77:74-5. 2004
    ..This appearance should be considered as a possible false positive in patients undergoing such treatment who are being investigated with PET scans...
  27. ncbi request reprint Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation
    H M Hunter
    Nottingham City Hospital, Nottingham NG5 1PB, UK
    Br J Haematol 128:496-502. 2005
    ..1% and 28.1% for melphalan/TBI and cyclophosphamide/TBI, respectively (P = 0.059). These results demonstrate that the type of conditioning for sibling allogeneic HSCT for myeloma has a major effect on transplant outcome...
  28. ncbi request reprint Immunotherapy in multiple myeloma--possibility or probability?
    S J Harrison
    ATMU and Cancer Division, Section of Experimental Haematology, University of Glasgow, Glasgow, UK
    Br J Haematol 130:344-62. 2005
    ..We look at the clinical immunotherapy trials reported to date and whether, in light of the current information, immunotherapy for MM is an achievable goal...
  29. ncbi request reprint Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study
    B Sirohi
    Haemato Oncology Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
    Bone Marrow Transplant 39:115-20. 2007
    ..The study drug was well tolerated. Treatment with hGH in physiological doses improves platelet recovery, but is not associated with a lower relapse rate or improved anthropometric parameters in patients receiving intensive chemotherapy...
  30. doi request reprint Position statement on the use of bortezomib in multiple myeloma
    G J Morgan
    Haemato Oncology Unit, Royal Marsden Hospital, London, UK
    Int J Lab Hematol 30:1-10. 2008
    ....
  31. ncbi request reprint Is long-term bisphosphonate administration associated with significantly increased circulating parathormone levels in patients with multiple myeloma?
    G Cook
    Eur J Endocrinol 149:467-8. 2003